Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conversion from calcineurin inhibitor to sirolimus versus continued calcineurin inhibitor in stable liver transplant recipients
2004-000935-27Phase 3Completed
- Sponsor
- Wyeth
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sirolimus in liver transplant (2 arms), sponsored by Wyeth. Primary endpoint: Change from baseline in calculated glomerular filtration rate at 12 months. Started May 2005; status: completed.
02
Drugs
sirolimus
03
Conditions
liver transplant
Beyond the preview
Go deeper on 2004-000935-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000935-27.